Literature DB >> 28544601

The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.

Jen-Fan Hang1,2,3, William H Westra1,4,5, David S Cooper6, Syed Z Ali1,7.   

Abstract

BACKGROUND: A recent revision in thyroid tumor nomenclature has resulted in a change from a malignant diagnosis (noninvasive follicular variant of papillary thyroid carcinoma) to one that is nonmalignant (noninvasive follicular thyroid neoplasm with papillary-like nuclear features [NIFTP]). The objective of the current study was to evaluate the impact of this change on the performance of the Afirma gene expression classifier (GEC).
METHODS: The authors retrospectively analyzed consecutive thyroid fine-needle aspiration specimens with indeterminate diagnoses on which GEC was performed. Surgical pathology material was reviewed with the reclassification of nodules into NIFTP.
RESULTS: GEC testing was performed on 384 fine-needle aspiration specimens diagnosed as atypia of undetermined significance (AUS) (304 cases) and suspicious for a follicular neoplasm (SFN) (80 cases) and yielded a suspicious result in 152 of the AUS cases (50%) and 50 of the SFN cases (63%). Thyroidectomy was performed on 177 patients. After reclassifying NIFTP, the positive predictive value of GEC decreased from 42% (95% confidence interval [95% CI], 39%-45%) to 24% (95% CI, 22%-26%) in the AUS group and from 23% (95% CI, 19%-27%) to 13% (95% CI, 9%-18%) in the SFN group. Total thyroidectomy was performed more frequently than a partial thyroidectomy in patients with AUS with a suspicious GEC result compared with pre-GEC controls (68% vs 49%; P = .037).
CONCLUSIONS: Reclassification of NIFTP significantly decreases the positive predictive value of GEC in indeterminate thyroid nodules. Nevertheless, the majority of patients with indeterminate thyroid nodules with a suspicious GEC result in the study institution have undergone total thyroidectomy. This finding raises concerns over reliance on a suspicious GEC result by clinicians to justify total thyroidectomy. Cancer Cytopathol 2017;125:683-91.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  Afirma; gene expression classifier; indeterminate thyroid nodules; noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)

Mesh:

Year:  2017        PMID: 28544601     DOI: 10.1002/cncy.21879

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  13 in total

Review 1.  Current methodologies for molecular screening of thyroid nodules.

Authors:  Elisabetta Macerola; Fulvio Basolo
Journal:  Gland Surg       Date:  2018-08

Review 2.  Noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP): a new entity.

Authors:  Elisabetta Macerola; Agnese Proietti; Fulvio Basolo
Journal:  Gland Surg       Date:  2020-01

Review 3.  Molecular Characterization of Thyroid Follicular Lesions in the Era of "Next-Generation" Techniques.

Authors:  Esther Diana Rossi; Pietro Locantore; Carmine Bruno; Marco Dell'Aquila; Pietro Tralongo; Mariangela Curatolo; Luca Revelli; Marco Raffaelli; Luigi Maria Larocca; Liron Pantanowitz; Alfredo Pontecorvi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-12       Impact factor: 6.055

4.  Features of Cytologically Indeterminate Molecularly Benign Nodules Treated With Surgery.

Authors:  Mayumi Endo; Kyle Porter; Clarine Long; Irina Azaryan; John E Phay; Matthew D Ringel; Jennifer A Sipos; Fadi Nabhan
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

5.  Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.

Authors:  Michiya Nishino; Roselyn Mateo; Holly Kilim; Anna Feldman; Amanda Elliott; Changyu Shen; Per-Olof Hasselgren; Helen Wang; Pamela Hartzband; James V Hennessey
Journal:  Thyroid       Date:  2021-06-22       Impact factor: 6.506

6.  Extending expressed RNA genomics from surgical decision making for cytologically indeterminate thyroid nodules to targeting therapies for metastatic thyroid cancer.

Authors:  Syed Z Ali; Allan Siperstein; Peter M Sadow; Allan C Golding; Giulia C Kennedy; Richard T Kloos; Paul W Ladenson
Journal:  Cancer Cytopathol       Date:  2019-04-24       Impact factor: 4.264

7.  Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.

Authors:  Cristina Alina Silaghi; Vera Lozovanu; Carmen Emanuela Georgescu; Raluca Diana Georgescu; Sergiu Susman; Bogdana Adriana Năsui; Anca Dobrean; Horatiu Silaghi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-13       Impact factor: 5.555

Review 8.  Preoperative Molecular Markers in Thyroid Nodules.

Authors:  Zeyad T Sahli; Philip W Smith; Christopher B Umbricht; Martha A Zeiger
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-18       Impact factor: 5.555

9.  Do patients with oxyphilic cell papillary thyroid carcinoma have a poor prognosis? Analysis of the surveillance, epidemiology, and end results database 2004-2013 with propensity score matching.

Authors:  Chunping Liu; Qiuyang Zhao; Wen Zeng; Chen Chen; Jie Ming; Shuntao Wang; Yiquan Xiong; Chao Zhang; Tianwen Chen; Zeming Liu; Tao Huang
Journal:  Oncotarget       Date:  2017-08-18

Review 10.  Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features in Asian Practice: Perspectives for Surgical Pathology and Cytopathology.

Authors:  Andrey Bychkov; Chan Kwon Jung; Zhiyan Liu; Kennichi Kakudo
Journal:  Endocr Pathol       Date:  2018-09       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.